All In Biotech

Drug Trial Radar · NCT06402331

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Actual

Start

Mar 5, 2024

Primary completion

Dec 23, 2026

Study completion Jan 23, 2031

Sponsor

Lead sponsor
Fusion Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
May 7, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I\&T). Patient population is adult participants with PSMA positive mCRPC who have had previous treatment with with 177Lu-PSMA-617 or another 177Lu-PSMA radioconjugate (RC). The purpose of the study is to determine the safety and tolerability, and recommended dose and regiment of FPI-2265.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • FPI-2265Drug

    Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac. Other Names: 225Ac-PSMA-I\&T

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency, duration, and severity of treatment-emergent adverse events (TEAEs)Time frame: From first dose until end of long-term follow-up, 5 years from end of treatment visit.
  2. Frequency and proportion of participants with PSA50 responseTime frame: From first dose until 12 weeks after the first administered dose of FPI-2265.

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Hoag Health Center Irvine

    Irvine, California

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California

  • University of California Los Angeles

    Los Angeles, California

  • UCSF School of Medicine

    San Francisco, California

  • Biogenix Molecular, LLC

    Miami, Florida

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • United Theranostics

    Glen Burnie, Maryland

  • BAMF Health

    Grand Rapids, Michigan

  • SSM Health Saint Louis University Hospital

    St Louis, Missouri

  • XCancer

    Omaha, Nebraska

  • New Mexico Oncology Hematology Consultants Ltd.

    Albuquerque, New Mexico

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone

    New York, New York

  • Memorial Sloan Kettering Cancer Center - NYC

    New York, New York

  • Oregon Health and Science University (OHSU, Knight Cancer Center)

    Portland, Oregon

  • VA North Texas Health Care System, Nuclear Medicine Service

    Dallas, Texas

  • The University of Texas Southwestern Medical Center

    Dallas, Texas

  • U.T. MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.